🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Clade C gp140 plus adjuvant

Found 11 matching trials

Safety and Immune Response to a Clade C DNA HIV Vaccine

PHASE1

The purpose of this study is to evaluate the safety and immune response to ...

Status

Completed

Location

Aurum Tembisa CRS

Start Date

2016-06-21

Trial ID

NCT02997969

Treatments Being Tested

DNA-HIV-PT123 vaccine Protein/MF59 vaccine Placebo

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

PHASE1

This study will evaluate the safety and immune response to the DNA-HIV-PT12...

Status

Completed

Location

Alabama CRS

Start Date

2016-12-07

Trial ID

NCT02915016

Treatments Being Tested

DNA-HIV-PT123 vaccine Bivalent Subtype C gp120/MF59 vaccine Bivalent Subtype C gp120/AS01B vaccine Placebo

Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.

PHASE1

The purpose of this study is to evaluate the safety and immunogenicity of H...

Status

Completed

Location

Emavundleni CRS

Start Date

2021-11-25

Trial ID

NCT05182125

Treatments Being Tested

AdC6-HIVgp140 AdC7-HIVgp140 CH505TF gp120 GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])Placebo

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

PHASE1

The purpose of this study is to assess the safety/tolerability of the 2 dif...

Status

Completed

Location

Multiple Locations

Start Date

2016-07-08

Trial ID

NCT02788045

Treatments Being Tested

Ad26.Mos.HIV Ad26.Mos4.HIV Clade C gp140 Placebo

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

PHASE1

The purpose of this study is to assess the safety and tolerability of vario...

Status

Completed

Location

Multiple Locations

Start Date

2014-12-22

Trial ID

NCT02315703

Treatments Being Tested

Ad26.Mos.HIV MVA-Mosaic gp140 DP Low-dose gp140 DP High-dose Placebo

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

PHASE2

The primary purpose of this study is to assess the preventive vaccine effic...

Status

Terminated

Location

UNC Lilongwe Project

Start Date

2017-11-03

Trial ID

NCT03060629

Treatments Being Tested

Ad26.Mos4.HIV Clade C gp140 Placebo

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

PHASE1

The primary purpose of this study is to assess safety/tolerability of 2 dif...

Status

Completed

Location

Beth Israel Deaconess Medical Center

Start Date

2018-03-05

Trial ID

NCT03307915

Treatments Being Tested

Ad26.Mos4.HIV MVA-Mosaic Clade C gp140 + Mosaic gp140 Placebo

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

PHASE1

The primary purpose of this study is to assess safety, tolerability of the ...

Status

Completed

Location

Multiple Locations

Start Date

2016-03-28

Trial ID

NCT02685020

Treatments Being Tested

Ad26.Mos.HIV Clade C gp140 Placebo

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

PHASE1

The primary purpose of this study is to assess safety/tolerability of the d...

Status

Completed

Location

Alabama Vaccine Research Clinic at UAB

Start Date

2017-03-31

Trial ID

NCT02935686

Treatments Being Tested

Ad26.Mos4.HIV Clade C gp140 plus adjuvant Clade C gp140/Mosaic gp140 plus adjuvant Placebo gp140 HIV Bivalent Vaccine

Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses

PHASE1

UKHVC Spoke 003 is a randomised Phase I, two centre study which will explor...

Status

Completed

Location

Surrey Clinical Research Centre, University of Surrey

Start Date

2013-06

Trial ID

NCT01922284

Treatments Being Tested

DNA MVA-C CN54rgp140 GLA-AF

Previous Next